

1. I have removed the codes of the trials as the codes do not provide much significance to the core topic.
2. On the page 11, the row 3 from below, trial ITI-007-303 you write on "standard of care medication". Would you describe this medication in a more detail? –

Ans: Thank you for bringing it up. In the original article by Corell et al. 2021, the authors have not mentioned the particulars of the previous antipsychotic medications. According to the study design, switching from the previous antipsychotic medication that was helpful to keep the symptoms of schizophrenia stable (Stable schizophrenia was defined as no hospitalization for psychiatric illness within 3 months of Day 1, a Clinical Global Impression – Severity (CGI-S) (ECDEU, 1976) score ≤ 4 at screening and baseline, and a score ≤ 4 on each of 4 core positive subscale items of the PANSS at baseline) to Lumateperone was helpful. However, I have corrected the sentence mentioning the “previous antipsychotic medications” instead of the standard of care medication.

3. Similarly, on the page 12, the rows 7 and 8 from above - trial ITI-007-303 - Part 2 you write on "the primary antipsychotic medication". A more comprehensive description of this medication would be better.

Ans: This is a reference from the same study as mentioned above, and no specific antipsychotic has been mentioned in the original study. I have phrased the sentence slightly differently to make it more understandable.

4. Conclusions: In the last sentence, you write about particular patient groups in which the newer antipsychotics may be beneficial. Which patient groups do you expect to profit from the new antipsychotics (brexpiprazole, cariprazine and lumateperone) and why?

Ans: As there is lack of data with these newer antipsychotic medications, it is difficult to predict which group will be more beneficial (eg. A group with a particular diagnosis or age group or co-morbidities) neither there is data on head-to-head comparison within these newer medications; therefore, more studies are necessary in near future.